Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. by F., Morabito et al.
Clinical Relevance of Immunophenotype in a
Retrospective Comparative Study of 297 Peripheral
T-Cell Lymphomas, Unspeciﬁed, and 496 Diffuse
Large B-Cell Lymphomas
Experience of the Intergruppo Italiano Linfomi
Fortunato Morabito, M.D.1
Andrea Gallamini, M.D.2
Caterina Stelitano, M.D.3
Vincenzo Callea, M.D.3
Cesare Guglielmi, M.D.4
Santo Neri, M.D.5
Antonio Lazzaro, M.D.6
Lorella Orsucci, M.D.7
Fiorella Ilariucci, M.D.8
Stefano Sacchi, M.D.9
Umberto Vitolo, M.D.7
Massimo Federico, M.D.10
1 Centro Trapianti Midollo Osseo, Azienda Osped-
aliera Bianchi-Melacrino-Morelli, Reggio Calabria,
Italy.
2 Struttura Complessa di Ematologia, Azienda Os-
pedaliera Santa Croce e Carle, Cuneo, Italy.
3 Divisione di Ematologia, Azienda Ospedaliera Bi-
anchi-Melacrino-Morelli, Reggio Calabria, Italy.
4 Unita` Operativa Complessa di Ematologia,
Azienda Ospedaliera Sant’Andrea, Universita` La
Sapienza, Rome, Italy.
5 Gruppo Italiano Linfomi Trial Ofﬁce, Modena, Italy.
6 Servizio di Oncologia Medica ed Ematologia, Os-
pedale Civile, Piacenza, Italy.
7 Struttura Complessa di Ematologia, Azienda Os-
pedaliera San Giovanni Battista, Turin, Italy.
8 Servizio di Ematologia, Azienda Ospedaliera Ar-
cispedale Santa Maria Nuova, Reggio Emilia, Italy.
9 Dipartimento di Oncologia ed Ematologia, Univer-
sita` di Modena e Reggio Emilia, Modena, Italy.
10 Cattedra di Oncologia Medica, Universita` di Mo-
dena e Reggio Emilia, Modena, Italy.
Supported by the Associazione Italiana contro le
Leucemie (Sezione Alberto Neri, Reggio Calabria,
Italy) and by the Associazione Angela Serra (Mod-
ena, Italy).
Institutions participating in the Intergruppo Italiano
Linfomi study of peripheral T-cell lymphoma in-
clude the following (principal investigators are
listed in parentheses): Struttura Complessa di
Ematologia, Azienda Ospedaliera Santa Croce e
Carle, Cuneo, Italy (A. Gallamini, D. Mattei, and R.
Calvi); Struttura Complessa di Ematologia, Azienda
Ospedaliera San Giovanni Battista, Turin, Italy (E.
Gallo and U. Vitolo); Cattedra di Ematologia, Uni-
versita` degli Studi di Torino, Turin, Italy (M. Boc-
cadoro, C. Tarella, and M. Ladetto); Divisione di
Onco-Ematologia, Istituto di Ricovero a Carattere
Scientiﬁco Candiolo, Turin, Italy (M. Aglietta and D.
Rota Scalabrini); Struttura Complessa di Medicina,
Ospedale di Biella, Biella, Italy (S. Fontana and A.
Tonso); Struttura Complessa di Medicina, Osped-
ale di Asti, Asti, Italy (E. Scassa, A. Ciravegna, and
R. Frieri); Cattedra di Clinica Medica, Universita`
Piemonte Orientale, Alessandria, Italy (G.L.
Gaidano); Divisione di Oncologia Medica C, Istituto
Nazionale Tumori, Milan, Italy (A.M. Gianni and L.
Devizzi); Cattedra di Ematologia, Universita` di Mi-
lano, Milan, Italy (M.T. Maiolo and L. Baldini);
Divisione di Ematologia, Ospedali Riuniti Bergamo,
Bergamo, Italy (T. Barbui and S. Cortellazzo); Unita`
Operativa di Ematologia, Spedali Civili Brescia,
Brescia, Italy (G. Rossi and E. Tucci); Divisione di
Ematologia, Istituto di Ricovero e Cura a Carattere
Scientiﬁco Policlinico San Matteo, Pavia, Italy (M.
Lazzarino and E. Brusamolino); Cattedra di Medi-
cina Interna, Universita` di Pavia/Istituto di Ricovero
e Cura a Carattere Scientiﬁco Policlinico San Mat-
teo, Pavia, Italy (P. Gobbi and M. Ghirardelli); Cat-
tedra di Ematologia, Universita` di Verona, Verona,
Italy (G. Pizzolo, G. Todeschini, and F. Benedetti);
Cattedra di Ematologia, Universita` di Padova,
Padua, Italy (G. Semenzato and R. Zambello); Di-
visione di Ematologia, Ospedale Regionale Bol-
zano, Bolzano, Italy (P. Coser and G. Quaini); Cat-
tedra di Ematologia, Universita` di Udine, Udine,
Italy (R. Fanin and F. Zaja); Divisione di Medica
Onco-Ematologica, Ospedale Civile, Piacenza, Italy
BACKGROUND. To assess the impact of T-cell/B-cell phenotype on clinical out-
come, the authors retrospectively compared patients who had peripheral T-cell
lymphoma, unspeciﬁed (PTCL-U), with patients who had diffuse large B-cell lym-
phoma (DLBCL).
METHODS. Two hundred ninety-seven cases of PTCL-U and 496 cases of DLBCL
that had been transferred from the ﬁles of the Intergruppo Italiano Linfomi or the
Gruppo Italiano Linfomi were integrated into a unique working ﬁle and reviewed
by the authors.
RESULTS. The PTCL-U group and the DLBCL group had signiﬁcantly different
distribution patterns with respect to patient age, gender, disease stage, perfor-
mance status (PS), the presence or absence of systemic “B” symptoms, the pres-
ence or absence of bulky disease, lactic acid dehydrogenase (LDH) levels, and
number of extranodal sites (ENS). A signiﬁcantly greater number of patients in the
DLBCL group experienced complete remission (P  0.0001). Multinomial logistic
regression analysis conﬁrmed that immunophenotype, PS, LDH concentration,
and number of ENS were independent predictors of response. At a median follow-
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up duration of 43 months, there was no observable difference in disease-free
survival (DFS) between patients with DLBCL and patients with PTCL-U; however,
multivariate analysis did reveal that poorer PS and bone marrow involvement were
signiﬁcantly associated with shorter DFS. Furthermore, although the overall sur-
vival (OS) curves associated with the T-cell and B-cell immunophenotypes were
signiﬁcantly different from each other at a median follow-up duration of 37
months (P  0.0012), Cox multivariate analysis excluded immunophenotype from
the ﬁnal OS model.
CONCLUSIONS. The ﬁndings made in the current study indicate that the natural
history of PTCL-U may differ from that of DLBCL. Patients with PTCL-U tended to
have less favorable clinical outcomes, although the observed difference in outcome
was only partially attributable to immunophenotype, which was independently
associated with response, but not with survival. Differences in prognostic factor
distributions between patients with PTCL-U and patients with DLBCL may ac-
count for some portion of the expected phenotype-associated risk. Cancer 2004;
101:1601–8. © 2004 American Cancer Society.
KEYWORDS: peripheral T-cell lymphoma, unspeciﬁed; diffuse large B-cell lym-
phoma; immunophenotype; prognosis; clinical outcome.
T/natural killer (T/NK)-cell lymphomas are rela-tively rare, accounting for only approximately
5–15% of all non-Hodgkin lymphomas encountered in
the Western world.1–4 Analysis of differentiation
marker expression has revealed that the majority of
T/NK-cell lymphomas arise due to the malignant
transformation of postthymic T cells and mature NK
cells5,6; consequently, such malignancies are known
generically as peripheral T-cell lymphomas (PTCLs). In
the updated Kiel classiﬁcation system,7 PTCLs are cat-
egorized into various subtypes and are also stratiﬁed
into two major prognostic groups (high-grade and
low-grade) on the basis of cell size–related criteria.
Although the Kiel classiﬁcation system is based on
clinicopathologic parameters, the prognostic signiﬁ-
cance of cell size has been questioned due to concerns
regarding reproducibility. Because of these concerns,
cell size is no longer considered a prognostic tool by
the World Health Organization (WHO) International
Classiﬁcation Project.8
From a clinical point of view, PTCL is considered
an aggressive malignancy, and in agreement with this
characterization, many investigators have found the
T-cell phenotype to be an independent adverse prog-
nostic factor2,3,9; others, however, have been unable to
conﬁrm this ﬁnding.10–13 PTCL is no longer included
in the WHO classiﬁcation system, and the signiﬁcant
clinical heterogeneity of malignancies that fall under
the umbrella of PTCL has been emphasized. In fact, a
number of well deﬁned clinicopathologic entities,
such as anaplastic large cell T-cell lymphoma, enter-
opathy-associated T-cell lymphoma, nasal-type T/NK-
cell lymphoma, angioimmunoblasticlike T-cell lym-
phoma, and hepatosplenic  T-cell lymphoma, have
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been identiﬁed within the PTCL category and are now
classiﬁed as separate malignancies. In addition, a new
subclass of PTCL has been identiﬁed and appropriately
termed peripheral T-cell lymphoma, unspeciﬁed (PTCL-
U); however, this is a blanket term that is used to de-
scribe a heterogeneous array of lymphomas with differ-
ing clinical features, histologic characteristics, genetic
alterations, responses to treatment, and associated prog-
noses. The complex nature of PTCL is evident,2,3,9–24 but
various indicators can assist in the prediction of a given
PTCL’s clinical course. In this context, the International
Prognostic Index (IPI),25 which was developed for the
assessment of aggressive lymphomas, represents a pos-
sible foundation on which to base a more appropriate
clinical deﬁnition of PTCL-U.26 Most previous studies
comparing outcomes between patients with PTCL and
patients with diffuse large B-cell lymphoma (DL-
BCL),2,3,9,11–13 another classiﬁcation that encompasses a
variety of distinct entities,27 have suffered from major
limitations related to the heterogeneity encountered
within each disease category. As a result, the ﬁndings of
these studies are no longer considered a suitable frame-
work for deﬁning prognosis-based subclasses of T-cell
lymphoma. Both the Revised European–American Lym-
phoma (REAL) Classiﬁcation System6 and the WHO sys-
tem8 deﬁne speciﬁc PTCL subtypes (e.g., PTCL-U) as
being unique on the basis of clinical outcome; thus, a
major limitation of past studies is that in most instances,
all patients with PTCL have been grouped together.
Recently, the Intergruppo Italiano Linfomi con-
ducted a retrospective study with the goals of more
accurately deﬁning the clinical and pathologic char-
acteristics of PTCL-U and designing a prognostic
model speciﬁcally for patients with this rare disease.28
In the current investigation, to assess the possible
independent prognostic role of immunophenotype,
we compared a series of patients affected by PTCL-U
with a series of patients affected by DLBCL, with all
patients having been sequentially included in pro-
spective trials involving anthracycline-containing che-
motherapy regimens.
MATERIALS AND METHODS
Patient Population
The Intergruppo Italiano Linfomi recently reported on
the construction of a prognostic model for patients
with PTCL-U.28 Using the working ﬁle employed in
that study—a ﬁle that contained information on his-
tologically conﬁrmed cases of PTCL-U (according to
the WHO criteria8)—we assessed candidate patients’
eligibility for the current study. Patients were required
1) to have complete clinical and hematologic data
available; 2) to have a minimum follow-up duration of
1 year, with the most recent control recorded  6
months before data collection; and 3) to have received
an anthracycline-based chemotherapy regimen.
A total of 297 cases of PTCL-U were included in
the current retrospective study. In addition, 496 his-
tologically conﬁrmed DLBCL cases that had been
transferred from the ﬁles of the Gruppo Italiano Lin-
fomi were included in the ﬁnal version of the working
ﬁle for the current study.
Treatment
Ninety percent of patients in the PTCL-U group re-
ceived CHOP (cyclophosphamide, doxorubicin, vin-
cristine, and prednisone) chemotherapy, a CHOP-like
regimen, or a third-generation chemotherapy regimen
(e.g., PROMACE-CytaBOM [methotrexate, prednisone,
doxorubicin, cyclophosphamide, etoposide, cytosine
arabinoside, bleomycin, and vincristine] or MACOP-B
[doxorubicin, cyclophosphamide, vincristine, metho-
trexate, bleomycin, and prednisone]), whereas the re-
maining 10% were treated with a regimen that in-
volved high-dose therapy and stem cell support. Most
patients in the DLBCL group (89%) received PROM-
ACE-CytaBOM chemotherapy, and all others received
the MACOP-B regimen.
Disease Staging and Assessment of Response
All patients underwent clinical disease staging. The
extent of disease was assessed using a procedure that
involved computed tomographic scanning of the chest
and abdomen as well as bone marrow (BM) biopsy.
Response to treatment was evaluated 1 month after
the end of induction therapy by performing all exam-
inations necessary to reassess previously detected ab-
normal ﬁndings. Complete remission (CR) was de-
ﬁned as the disappearance of all initial clinical
evidence of disease with accompanying normalization
of all biochemical parameters and radiographic ﬁnd-
ings that were determined to be abnormal before the
start of treatment; normalization of BM, if initially
involved, was also required. Furthermore, patients
who achieved CR during therapy but experienced dis-
ease recurrence within 30 days after the completion of
treatment were classiﬁed as not having experienced a
response. Partial remission (PR) was deﬁned as a re-
duction of  50% in the largest tumor dimension at
each anatomic site of measurable disease for  1
month. ‘No response’ (NR) was deﬁned as stabiliza-
tion or progression of disease or tumor regression by
 50%. All evaluations of clinical stage and response
to treatment were based on the original data recorded
by local physicians.
Progressive disease (PD) was deﬁned as an in-
crease of  25% in tumor size or the appearance of
any new neoplastic lesion. All patients who died pre-
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maturely due to disease progression or treatment-
related toxicity were considered to have experienced
treatment failure and were included in the NR/PD
group for the purposes of the current analysis.
Statistical Analysis
All calculations were performed using the SPSS statis-
tical software package (Version 11.0; SPSS Inc., Chi-
cago, IL). Along with immunophenotype, the follow-
ing clinical features were analyzed as potential
prognostic factors: age, gender, performance status
(PS), symptoms, disease stage, lactic acid dehydroge-
nase (LDH) concentration, hemoglobin (Hb) concen-
tration, number of extranodal disease sites (ENS),
erythrocyte sedimentation rate (ESR), presence or ab-
sence of bulky disease, and presence or absence of BM
involvement. Age, Hb and LDH concentrations, ESR,
and number of ENS were transformed into binary
variables as appropriate. Statistical comparisons in-
volving binary variables were performed using two-
way tables for the Fisher exact test and multiway ta-
bles for the Pearson chi-square test. Multivariate
analysis was performed via multinomial logistic re-
gression, because the dependent variable was re-
stricted to three possible values (CR, PR, and NR/PD).
Because the response evaluation date was not avail-
able in all cases, disease-free survival (DFS) for pa-
tients who achieved CR was calculated from the time
of diagnosis to the time of recurrence or death using
the Kaplan–Meier method. Overall survival (OS) was
calculated as the interval between diagnosis and death
due to any cause or, for surviving patients, as the
interval between diagnosis and the most recent fol-
low-up assessment. Prognostic groups were evaluated
on univariate analysis (log-rank test), and the effects of
potential prognostic variables on survival (signiﬁcance
threshold, P 0.1) were assessed in a stepwise fashion
according to the Cox regression method. P  0.05 was
considered indicative of signiﬁcance in all statistical
calculations.
RESULTS
Patient Characteristics
Table 1 compares the clinical and hematologic char-
acteristics of patients with PTCL-U and patients with
DLBCL. Distribution patterns with respect to patient
age, gender, disease stage, PS, the presence of sys-
temic symptoms, the presence of bulky disease, LDH
concentration, and number of ENS were signiﬁcantly
different between these two groups. Speciﬁcally, male
patients (P  0.0001), patients with advanced-stage
disease (P  0.0001), patients presenting with poor PS
(P  0.0001), patients with  2 ENS (P  0.0001),
patients with systemic symptoms (P  0.0001), and
patients with abnormal LDH levels (P  0.0005) were
signiﬁcantly more common in the PTCL-U group. In
contrast, older patients (P  0.015) and patients with
bulky disease (P 0.005) were signiﬁcantly more com-
mon in the DLBCL group. The two patient groups also
differed signiﬁcantly with respect to IPI, with a greater
percentage of patients in the DLBCL group having
favorable IPI scores (P  0.0001). No other signiﬁcant
differences were noted.
Analysis of Response and Response Duration
Response to therapy was assessable in 95.6% of all
patients (758 of 793). Overall, 544 of these patients
(72%) experienced CR, 96 (13%) experienced PR, and
118 (13%) had NR/PD. Analysis of responses accord-
ing to B-cell/T-cell phenotype revealed a signiﬁcantly
greater number of cases of CR in the DLBCL group (P
 0.0001) (Table 2). Furthermore, univariate analysis
revealed highly signiﬁcant correlations between CR
and favorable PS, the absence of systemic symptoms,
early-stage disease, normal LDH levels, normal Hb
levels, the presence of  1 ENS, ESR  15 mm/hr, and
the absence of BM involvement. Multinomial logistic
regression analysis identiﬁed immunophenotype (P 
0.0001), PS (P  0.0001), LDH concentration (P 
TABLE 1
Comparison of the Primary Clinical Characteristics of Patients with
PTCL-U and Patients with DLBCL at the Time of Disease Onset
Characteristic
% of patients
PaPTCL-U DLBCL
Age  60 yrs 27 36 0.015
Female gender 32 45  0.0001
Stage III–IV diseaseb 78 65  0.0001
WHO PS  2 29 10  0.0001
B symptoms present 49 32  0.0001
Bulky disease present 17 26 0.005
Abnormal LDH levels 47 35 0.005
Abnormal Hb levels 24 23 ns
BM involvement present 32 27 ns
 2 extranodal sites involved 41 31 0.003
IPI score
0–1 32 43
2 26 29  0.0001c
3 25 20
 3 17 8
ESR  15 mm/hr 69 69 ns
PTCL-U: peripheral T-cell lymphoma, unspeciﬁed; DLBCL: diffuse large B-cell lymphoma; WHO: World
Health Organization; PS: performance status; LDH: lactic acid dehydrogenase; Hb: hemoglobin; ns: not
signiﬁcant; BM: bone marrow; IPI: International Prognostic Index; ESR: erythrocyte sedimentation rate.
a Fisher exact test.
b Ann Arbor staging system.
c Chi-square test.
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0.004), and number of ENS (P  0.04) as independent
predictors of response.
Of the 544 patients who experienced CR, 469 (in-
cluding 159 with PTCL-U) were evaluable for disease
recurrence; 249 of these patients (including 91 with
PTCL-U) experienced recurrence or died during CR.
After a median follow-up duration of 43 months, there
was no difference in DFS between patients with DL-
BCL and patients with PTCL-U (Fig. 1). Furthermore,
no signiﬁcant difference in DFS was observed in asso-
ciation with age  60 years, the absence of systemic
symptoms, or the presence of  1 ENS and ESR  15
mm/hr (Table 3). In contrast, advanced-stage disease,
abnormal serum LDH levels, poor PS, and BM involve-
ment all were associated with signiﬁcantly reduced
DFS; however, only poor PS (P  0.025) and BM in-
volvement (P  0.025) remained signiﬁcantly corre-
lated with DFS on multivariate analysis (Table 3).
Analysis of Survival
After a median follow-up duration of 37 months (67
months for surviving patients), 392 patients had died.
As expected, the survival curves associated with the
T-cell and B-cell immunophenotypes were statistically
different from each other (Fig. 2). Fifty-six percent of
all patients with DLBCL were projected to be alive at 5
years, compared with 42% of all patients with PTCL-U
(P  0.0012). Univariate analysis revealed that age
 60 years (P  0.0051), poor PS (P  0.00001), the
presence of systemic symptoms (P  0.00001), ad-
vanced disease stage (P  0.00001), elevated serum
LDH levels (P  0.00001), the presence of bulky dis-
ease (P  0.0425), BM involvement (P  0.00001),
involvement at  2 ENS (P  0.00001), ESR  15
mm/hr (P 0.00001), and abnormally low Hb levels (P
 0.00001) also were signiﬁcantly predictive of re-
TABLE 2
Univariate and Multivariate Logistic Regression Analyses of Potential Predictors of Response
Variable
% of patients
Univariate
Pa
Multivariate
PbCR PR NR/PD
Histology: DLBCL vs. PTCL-U 82 vs. 56 8 vs. 20 10 vs. 24  0.0001  0.0001
Age (yrs):  60 vs.  60 73 vs. 70 14 vs. 10 13 vs. 20 0.059 ns
Gender: male vs. female 69 vs. 76 14 vs. 10 17 vs. 14 0.061 ns
WHO PS:  1 vs.  2 78 vs. 47 10 vs. 23 12 vs. 30  0.0001  0.0001
B symptoms: yes vs. no 62 vs. 78 17 vs. 10 21 vs. 12  0.0001 ns
Disease stage: I–II vs. III–IVc 83 vs. 67 7 vs. 15 10 vs. 18  0.0001 ns
LDH levels: normal vs. abnormal 80 vs. 60 10 vs. 17 10 vs. 23  0.0001 0.004
Bulky disease: no vs. yes 72 vs. 71 13 vs. 12 15 vs. 17 ns —
BM involvement: yes vs. no 65 vs. 74 17 vs. 11 18 vs. 15 0.027 ns
No. of extranodal sites:  1 vs.  2 78 vs. 61 10 vs. 16 12 vs. 23  0.0001 0.040
ESR (mm/hr):  15 vs.  15 81 vs. 70 10 vs. 13 9 vs. 17 0.007 ns
Hb levels: normal vs. abnormal 76 vs. 62 11 vs. 15 13 vs. 23 0.001 ns
CR: complete remission; PR: partial remission; NR/PD: no response/progressive disease; DLBCL: diffuse large B-cell lymphoma; PTCL-U: peripheral T-cell lymphoma, unspeciﬁed; ns: not signiﬁcant; WHO: World
Health Organization; PS: performance status; LDH: lactic acid dehydrogenase; BM: bone marrow; ESR: erythrocyte sedimentation rate; Hb: hemoglobin.
a Pearson chi-square test.
b Multinomial logistic regression.
c Ann Arbor staging system.
FIGURE 1. Kaplan–Meier analysis of disease-free survival according to
histologic subtype. No difference was found between the two patient groups (P
 0.1). DLBCL: diffuse large B-cell lymphoma; PTCL-U: peripheral T-cell
lymphoma, unspeciﬁed.
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duced OS. Ultimately, Cox multivariate analysis ex-
cluded immunophenotype from the ﬁnal OS model,
which included age (risk ratio [RR], 1.3; P  0.023), PS
(RR, 1.9; P  0.0001), LDH concentration (RR, 1.7; P 
0.0001), presence or absence of bulky disease (RR, 1.4;
P  0.011), and presence or absence of BM involve-
ment (RR, 1.3; P  0.048) (Table 4).
DISCUSSION
The efforts of the International Lymphoma Study
Group and the diagnostic criteria set forth by the REAL
and WHO classiﬁcation systems have led to clariﬁca-
tion of the deﬁnition of PTCL,6,8 although character-
ization of the role of the T/NK-cell immunophenotype
in prognostic workup remains a signiﬁcant challenge.
Montalban et al.14 compared PTCL (which was limited
to the prevalent lymph node subtype, as deﬁned by
the WHO International Classiﬁcation Project,8 due to
the heterogeneity of PTCLs with respect to clinical
presentation) with the equally aggressive DLBCL. Sev-
eral studies have suggested that for patients with
PTCL, outcome can be predicted on the basis of clin-
ical parameters, and there is general agreement—with
some exceptions10–13—that PTCL is associated with
poorer survival compared with B-cell lymphoma2,3,9;
however, comparisons of PTCL with DLBCL in these
studies were inadequate, as individual REAL or WHO
subtypes of PTCL were not considered separately from
one another.
The current retrospective analysis, which involved
783 cases of malignant disease with either T-cell (n 
297) or B-cell phenotype (n 496), is one of the largest
comparison studies of PTCL-U and DLBCL performed
to date. In this study, we assessed the impact of im-
munophenotype on clinical response and response
duration. A signiﬁcantly lower CR rate was observed in
the PTCL-U group compared with the DLBCL group
(56% vs. 82%), a ﬁnding that was consistent with pre-
viously reported CR rates (40–69%) in patients with
TABLE 3
Univariate and Multivariate Analyses of Potential Predictors of Disease-Free Survival
Variable
Median DFS
(mos)
Univariate
Pa
Multivariate
Pb RR (95% CI)
Histology: DLBCL vs. PTCL-U 81 vs. 51 0.1 ns —
Age (yrs):  60 vs.  60 91 vs. 47 0.0837 ns —
Gender: male vs. female 71 vs. 51 ns —
WHO PS:  1 vs.  2 74 vs. 27 0.0228 0.025 1.6 (1.1–2.4)
B symptoms: yes vs. no 89 vs. 49 0.1 ns —
Disease stage: I–II vs. III–IVc Not reached vs. 39 0.0002 ns —
LDH levels: normal vs. abnormal 90 vs. 28 0.0037 ns —
Bulky disease: no vs. yes 73 vs. 47 ns —
BM involvement: yes vs. no 94 vs. 33 0.0005 0.025 1.5 (1.0–2.3)
No. of extranodal sites:  1 vs.  2 81 vs. 38 0.1 ns —
ESR (mm/hr):  15 vs.  15 96 vs. 50 0.0889 ns
Hb levels: normal vs. abnormal 59 vs. 72 ns —
DFS: disease-free survival; RR: risk ratio; CI: conﬁdence interval; DLBCL: diffuse large B-cell lymphoma; PTCL-U: peripheral T-cell lymphoma, unspeciﬁed; ns: not signiﬁcant; WHO: World Health Organization; PS:
performance status; LDH: lactic acid dehydrogenase; BM: bone marrow; ESR: erythrocyte sedimentation rate; Hb: hemoglobin.
a Log-rank test.
b Cox regression analysis.
c Ann Arbor staging system.
FIGURE 2. Overall survival of 793 patients according to histologic subtype.
Projected survival was signiﬁcantly longer (P  0.0012) for patients who had
diffuse large B-cell lymphoma (DLBCL) compared with patients who had
peripheral T-cell lymphoma, unspeciﬁed (PTCL-U).
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PCTL-U.3,16,18,24 Furthermore, T-cell immunopheno-
type, along with clinical parameters such as poor PS,
abnormal LDH levels, and involvement of  2 ENS,
were identiﬁed as potential independent predictors of
poor response. Notably, however, the signiﬁcance of
T-cell histology in predicting reduced DFS was lost on
multivariate analysis, whereas poor PS and BM in-
volvement maintained their prognostic signiﬁcance.
Thus, based on the ﬁrst part of the current analysis, we
can conclude that T-cell immunophenotype is associ-
ated with a higher risk of failure to achieve CR; how-
ever, if a CR is achieved, its duration is related primar-
ily to speciﬁc clinical characteristics, rather than to
disease immunophenotype. This unusual ﬁnding may
represent a major problem for patients with PTCL-U,
as Song et al.29 have reported that the beneﬁt associ-
ated with autologous BM transplantation for such pa-
tients is negligible.
As expected, the survival curves associated with
the T-cell and B-cell immunophenotypes were statis-
tically different from each other; the 5-year survival
rate for patients with DLBCL was 56%, compared with
42% for patients with PTCL-U. The median OS dura-
tion for patients with PTCL-U was 39 months, greater
than has been reported elsewhere.3,16–18,23 This dis-
crepancy may be attributable, at least in part, to the
exclusion of patients who were not treated with an-
thracycline-based regimens from the current study. In
addition to immunophenotype, various tumor-related
and host-related characteristics were found to be sig-
niﬁcant predictors of reduced OS on univariate anal-
ysis. Further highlighting the signiﬁcance of clinical
presentation was the exclusion of disease histology
from the ﬁnal multivariate OS model; only age, per-
formance status, LDH concentration, bulky disease
(presence or absence), and BM involvement (presence
or absence) remained signiﬁcant following Cox multi-
variate analysis. This unexpected ﬁnding differs from
those that have been reported by other investigators.
For example, Gisselbrecht et al.9 examined 288 cases
of PTCL and 1595 cases of B-cell lymphoma and found
that patients with T-anaplastic large cell lymphoma (n
 60) had a 5-year OS rate of 64%, superior to the
corresponding rates for patients with other PTCL sub-
types (35%) and patients with DLBCL (53%). In that
study, nonanaplastic subtype (n  228) remained sig-
niﬁcant on multivariate analysis (with IPI score in-
cluded in the multivariate model) and therefore was
deemed an independent adverse prognostic factor.
In conclusion, the results of the current study
suggest that the natural history of PTCL-U may in fact
be different from that of DLBCL. Overall, patients with
PTCL-U had a less favorable clinical outcome, al-
though this difference in outcome was only partially
attributable to immunophenotype, which was inde-
pendently associated with CR but not independently
correlated with survival. The relative prevalence of
adverse prognostic factors in the PTCL-U group has
also been reported by Melnyk et al.3 and Gisselbrecht
et al.9 and can account for some portion of the ex-
pected phenotype-associated risk.
An alternative and widely held belief is that the
PTCL-U category encompasses a heterogeneous array
of malignant subtypes that have not yet been fully
TABLE 4
Univariate and Multivariate Analyses of Potential Predictors of Overall Survival
Variable Median OS (mos)
Univariate
Pa
Multivariate
Pb RR (95% CI)
Histology, DLBCL vs. PTCL-U 94 vs. 39 0.0012 ns —
Age (yrs):  60 vs.  60 93 vs. 47 0.0051 0.023 1.3 (1.0–1.6)
Gender: male vs. female 52 vs. 89 0.1 ns —
WHO PS:  1 vs.  2 94 vs. 13  0.00001  0.0001 1.9 (1.4–2.5)
B symptoms: yes vs. no 95 vs. 30  0.00001 ns —
Disease stage: I–II vs. III–IVc Not reached vs. 45  0.00001 ns —
LDH levels: normal vs. abnormal 117 vs. 23  0.00001  0.0001 1.7 (1.4–2.2)
Bulky disease: no vs. yes 81 vs. 33 0.0425 0.011 1.4 (1.0–1.8)
BM involvement: yes vs. no 95 vs. 38 0.0001 0.048 1.3 (1.0–1.7)
No. of extranodal sites:  1 vs.  2 94 vs. 37  0.00001 ns —
ESR (mm/hr):  15 vs.  15 117 vs. 49  0.00001 ns —
Hb levels: normal vs. abnormal 94 vs. 33 0.0001 ns —
OS: overall survival; RR: risk ratio; CI: conﬁdence interval; DLBCL: diffuse large B-cell lymphoma; PTCL-U: peripheral T-cell lymphoma, unspeciﬁed; ns: not signiﬁcant; WHO: World Health Organization; PS:
performance status; LDH: lactic acid dehydrogenase; BM: bone marrow; ESR: erythrocyte sedimentation rate; Hb: hemoglobin.
a Log-rank test.
b Cox regression analysis.
c Ann Arbor staging system.
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characterized. Lending support to this idea, Tsuchiya
et al.30 recently found that patients’ prognoses varied
according to the expression of certain Th1/Th2 cell–
associated chemokine receptors and markers. This hy-
pothesis could at least partially explain why the T-cell
phenotype had differing effects on response and sur-
vival in the current study. Future genetic proﬁling
studies involving large patient cohorts could lead to a
biologic explanation for the observed association be-
tween PTCL-U and poor outcome.
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